Belfast-based biotech, or techbio as Amply likes to call it, has raised further seed money this year and has secured over £1.4 million in grant funding to enhance its AI-powered drug discovery platform.
Not to be confused with Tech.eu jobs board partner Amply, the Belfast-based biotech startup Amply has reported today that it has raised over £1.4 million in grant financing. The money will be used by the business to advance the development of its AI-powered drug discovery platform.
The funding comes in two installments: £835,000 from Innovate UK and Innosuisse will go toward researching and creating a novel RNAi therapy for Acute Myeloid Leukemia, while £602,000 from Innovate UK will enable Amply to concentrate on creating a novel nebulized antimicrobial product for MDR-TB. In the second quarter of this year, Amply, a spin-out from Queens University Belfast, plans to raise an additional £1.4 million through a seed funding round.
Co-fund NI, an organization run by Clarendon Fund Managers with backing from Invest NI, the British Business Bank, QUBIS, the Helix Way Partnership, Techstars, and angel investors from the Halo Business Angel Network (HBAN) are among the current backers of Amply.
